- The importance of research
- Latest research findings
- Current research being undertaken
- What are clinical trials
- Trials open to new patients
- New trials yet to be started
- Trials in follow up phase
- Relevant websites
Research is ongoing, it never stops in the drive to prevent and cure breast cancer.
Breast cancer is not just one disease; there are many types and stages all of which need different treatments. That is why we cannot rest on our laurels, and why we must continue to drive our research efforts to achieve the best – the best outcomes, the best preventative measures, the best cure.
The Waikato Breast Cancer Research Trust engages in local and international breast cancer research trials to ensure wāhine/women receive the very best treatment for the type of breast cancer they are suffering from. Women participating in good quality cancer trials, on average, do better in responding to treatment, yet only a minority have this opportunity.
Through good quality research and the contribution of wāhine/women, research staff, scientists and clinicians, steady advances have been made in breast cancer care. These advances have resulted in improved chances of a good outcome for women diagnosed with the disease.
Major advances in controlling breast cancer include:
- our ability to use breast conserving surgery or less radical mastectomy (removal of the whole breast) for many wāhine/women
- saving lives with regular mammography screening
- better drug treatments, both chemotherapy and hormonal therapies
- the entry into the era of highly targeted therapies aimed at breast cancers which have specific features present e.g. Herceptin for HER2 positive breast cancer
- reducing local recurrence with improvements in radiotherapy
- developments of breast reconstruction and sentinel node surgical techniques
- breast cancer prevention
Improvements in long-term outcome for women with estrogen receptor positive (ER+) early stage breast cancer treated with 5 years of endocrine therapy: Analyses of 82,598 women in the Early Breast Cancer Trialists’ Collaborative Group (EBCTCG) database
The effects of comorbidity on breast cancer treatment and outcomes in New Zealand
Dr Mel Edwards (Doctoral Research Fellow, University of Auckland) commenced her PhD on this topic in January 2016. This involves investigating the management of wāhine/women with breast cancer in addition to other medical problems and their ultimate outcomes. As this group of women are often under-represented in clinical trials and with complex medical needs it will be useful to determine where there may be opportunities to improve their care.
A PhD project examining health literacy in Māori wāhine
With a view to interventions to see what can be done to help diagnose breast cancer at an earlier stage amongst Māori wāhine. This project was commenced in 2015, with Tamati Peni, undertaking this work. Tamati worked with our breast cancer register team on the over 2012-2014 during which time he developed an indepth knowledge of the disease and many of the issues contributing to inequity in outcomes.
Tamati’s PhD project is supervised by Professor Ross Lawrenson, Professor of Population Health, University of Waikato and Clinical Director, Planning & Funding, Waikato District Health Board.
Post mastectomy recurrence study
This research is investigating post mastectomy recurrence and survival for Auckland and Waikato wāhine/women with newly diagnosed breast cancer to try and determine: When is radiotherapy necessary?
This project is made possible by a grant from the NZ Breast Cancer Foundation. A/Professor Ian Campbell (Surgeon, Waikato District Health Board & WBCRT Chair) is heading this project).
When is enough, enough? Margins of excision after breast conservation surgery for breast cancer
This study seeks to determine what is the optimal margin of excision and how does this vary with tumour biology, patient factors, adjuvant therapy, and the other variables, many of which were not available in previous reported series. With this information, NZ and international clinicians can give more informed advice and make more informed decisions on this very common breast cancer treatment dilemma.
This project has been made possible by a grant from the NZ Health Research Council and NZ Breast Cancer Foundation joint initiative research grant. Associate Professor Ian Campbell (Surgeon, Waikato District Health Board & WBCRT Chair) is heading this project).
Metastatic behaviour and outcomes of breast cancer subtypes
Among breast cancer patients who develop distant metastases, there is a marked variability in the clinical course, including pattern of metastatic spread. The project involves a retrospective observational study of breast cancer patients who developed distant metastases, focusing on the association between breast cancer subtype and clinical course, including organ-specific metastases.
Dr Marion Kuper-Hommel (Medical Oncologist, Waikato District Health Board & WBCRT Trustee) is heading this project.
Development and assessment of predictive models of outcome in breast cancer in New Zealand
The goal of this upcoming project is to identify factors related to breast cancer care outcomes for wāhine/women in New Zealand, to assess existing predictive models, and to develop better predictive methods to assess prognosis. The outcome of breast cancer depends on many factors. If the prognosis of an individual patient can be predicted with some accuracy, this information is valuable to the treating doctor and the patient as it will impact on how they deal with the disease.
This includes therapeutic choices; for example, a high proportion of patients with primary breast cancer meet eligibility criteria for adjuvant systemic therapy, but amongst this group are patients at very little risk of recurrence. It has been argued that in a substantial proportion of patients at lower risk, but treated according to current guidelines, the loss of quality of life from toxicity may outweigh the small or absent survival benefit. In contrast, patients at high risk may justify modified treatment or follow-up procedures.
This project is to be carried out by a PhD student (University of Auckland) under the supervision of Professor Mark Elwood (Professor of Cancer Epidemiology, University of Auckland).
Sentinel node study
This research is investigating the regional recurrence rate in patients undergoing sentinel node biopsy alone for breast cancer in NZ. It aims to identify tumour or sentinel node based factors that can help predict regional recurrence.
This project was made possible from a grant from the NZ Breast Cancer Foundation.
What are clinical trials?
Clinical trials form the link between discoveries made in the cancer research laboratory and making new treatment available for people diagnosed with cancer. It is extremely important that all new therapies and procedures associated with any cancer care be accurately proven and long-term safety determined before they can be recommended for general or standard use.
What types of clinical trials are there for breast cancer?
Detection or screening trials evaluate the best approach to find a cancer in its early stages; for example mammograms (breast x-rays).
Prevention trials test new approaches; e.g. use of medicines or healthy lifestyle changes that may lower the risk of getting certain cancers.
Treatment trials test new treatment; e.g. drugs such as chemotherapy or hormonal treatments. New radiotherapy or surgical techniques are also tested. Counselling and psychological support or ways of providing better communication are also part of treatment trials.
Why participate in a trial?
Participation in a clinical trial does assist with the advancement of medical knowledge.
People take part in trials for a number of reasons. They may receive a new treatment before it is widely available to other cancer patients. Evidence shows people can also have better outcomes because they have been involved in a trial, even if they have received standard treatment. This may be because most participants on a clinical trial receive carefully and most often rigorously monitored treatment and follow-up.
Is a trial suitable for you?
Your Oncologist (Cancer Doctor or Specialist) may suggest that you consider taking part in a clinical trial that they may be contributing to or know of one being done at another centre.
If you are interested in taking part in a study ask your Oncology Doctor.
Your Oncology Doctor will explain a trial to you including the known benefits and risks of a new treatment or procedure. A patient information sheet giving the details of the research will also be given to you before you agree (consent) to take part in a trial.
Why are clinical trials important in breast cancer care?
All the major advances in controlling breast cancer have been the result of clinical trial research. This includes:
- our ability to use breast conserving surgery, instead of mastectomy (removal of the whole breast) for many women
- saving lives with regular mammograms
- the entry into the era of highly targeted therapies aimed at breast cancers which have specific features present, e.g. Herceptin for HER 2 positive breast cancer
- improvements in radiotherapy and surgical techniques
- breast cancer prevention
It is extremely important that all new therapies and procedures be scientifically proven and long term safety determined before they can be recommended for general or standard use.
Where are the participating centres for breast cancer trials in New Zealand?
In New Zealand, breast cancer clinical trials are available at Cancer Centres or Breast Clinics at North Shore, Auckland, Waikato, Palmerston North, Welllington, Christchurch and Dunedin Public Hospitals.
Some Cancer Specialists in private clinics participate in breast cancer clinical trials. Do ask your treating Oncology Doctor if there is a trial available for your situation.
The POSNOC trial is a clinical research trial available in NZ looking at the armpit treatment provided to women diagnosed with early stage breast cancer and will help determine if axillary dissection is no longer needed meaning that some wāhine/women will be able to avoid unnecessary treatment and long term side effects of treatments.
POSNOC is of considerable importance in terms of improving outcomes for women with breast cancer and also in understanding breast biology.
The purpose of this study is to see whether a specialised laboratory test (Prosigna (PAM50) Assay) of breast cancer tissue can be used to choose wāhine / women who can safely avoid radiation therapy because there is a low risk of the cancer coming back.
The EXPERT trial presents a unique opportunity to improve personalised use of radiation therapy in patients with early breast cancer according to their individual risks of local recurrence.
The trial is looking into lymph node grafting for upper limb lymphoedema following breast cancer treatment. With an aim of determining whether lymph node grafting plus standard lymphoedema therapy produces a greater reduction in lymphoedema volume and improved quality of life for those with upper limb lymphoedema.
There are no trials yet to be started currently.
This is a randomised, open label, Phase 3 study of Abemaciclib combined with standard adjuvant endocrine therapy alone for patients with high risk, node positive, early stage, hormone receptor positive, HER2 negative breast cancer. The aim of the MonarchE trial is to evaluate whether the combination of the drug Abemaciclib plus standard hormonal (endocrine) therapy improves outcomes in women and men with a certain type of breast cancer compared to the standard treatment of hormonal therapy alone. Abemacicilib is ian oral drug which stops the production of proteins in the body called CDK4 and CDK6, which are responsible for promoting cell growth. This mechanism has been shown to have antitumour activity and significantly reduce breast cancer tumour growth.
The International Breast Cancer Intervention Study II
The International Breast cancer Intervention Study II (IBIS II) is evaluating whether the drug anastrozole can prevent breast cancer in wāhine/women at elevated risk (mostly due to a strong family history of breast cancer).
The Waikato is also a centre for the IBIS II bone sub-study, available for wāhine/women participating in the IBIS II prevention study. This research evaluates the impact of anastrozole on bone health and whether the drug risedronate can prevent loss of bone density in these women.
We are also participating in the IBIS II mammographic breast density sub-study. Breast density is a known marker of increased risk for breast cancer.
IBIS II DCIS
There is a second part to the IBIS II trial where the use of anastrozole is being compared to tamoxifen for wāhine/women with hormonally sensitive ductal carcinoma in situ (DCIS). DCIS is a non-invasive breast cancer.
The Suppression of Ovarian Function Trial (SOFT)
The Suppression of Ovarian Function Trial (SOFT) is testing the role of ovarian function suppression and the role of exemestane in premenopausal wāhine/women.
First results in 2014 showed that ovarian suppression reduces breast cancer recurrence for some young women.
Quality of life and breast reconstruction study (QoLid)
A prospective Quality of Life study of Immediate & Delayed (QoLid) breast reconstruction in women undergoing mastectomy and radiotherapy for breast cancer.
Radiotherapy has a detrimental effect on outcomes from breast reconstruction for some women, especially for women undergoing implant based reconstruction. For this reason, some surgeons recommend delaying radiotherapy until after all of the therapy e.g. chemotherapy, is complete. This is a controversial issue with little good evidence to support the best approach.
The main aim of the study is to assess the quality of life and reconstruction outcomes from immediate & delayed breast reconstruction in women undergoing mastectomy and post-mastectomy radiotherapy for breast cancer. All recruited patients (immediate or delayed breast reconstruction or non-reconstructed patients) will be asked to complete questionnaires at set time frames throughout the study.
The questionnaires will assess quantitative & qualitative factors affecting quality of life throughout the treatment of their breast cancer and would assess whether breast reconstruction, timing of breast reconstruction, complications from surgery or adjuvant treatment regimes affect the patient’s overall quality of life.
This is a pilot study. Waikato Hospital is collaborating with the Royal North Shore Hospital and the Breast & Surgical Oncology Centre at The Poche Centre in North Sydney, in this first prospective study in Australia and New Zealand, assessing the quality of life of these women.
This study was made possible from grants from the Waikato Medical Research Foundation, Waikato Bay of Plenty Cancer Society and Jumble Around (Second hand store, Cambridge).
Sentinel node biopsy clinical trials (SNAC2)
Sentinel Node biopsy versus Axillary Clearance Trial Part 2 (SNAC2). The initial SNAC Part 1 study, aimed to answer the question: “Does sentinel node biopsy (removal of the first lymph nodes related to the breast cancer, result in reduced side effects from surgery compared to standard axillary clearance?”. Part 2 of this research evaluates the use of sentinel node biopsy in women with larger breast cancers or with more than one cancer in the breast, to answer the very important question; “Does sentinel node biopsy result in increased local recurrence or decreased survival, and if so, for which group of women is this the case and for whom is axillary clearance really necessary? This is a Breast Surgeons Australia and New Zealand clinical trial.
Selective Use of Postoperative Radiotherapy AftEr MastectOmy or SUPREMO trial.
Radiotherapy is routinely given to women after mastectomy, when they are at “higher” risk of their breast cancer returning (e.g. when the tumour is large or when there is four or more lymph nodes involved by cancer). International controversy continues regarding which “moderate” risk group of women require radiotherapy after mastectomy and this international randomised trial is underway to attempt to further address this issue.
Trial Assigning Individualised Options for Treatment: The TAILORx Trial
This trial is investigating the Oncotype DX assay which is a prognostic laboratory test to predict breast cancer recurrence in women with early stage hormone receptor positive and node negative breast cancer. The aim of the research is to investigate whether women with an intermediate “recurrence score” (11-25) benefit from chemotherapy in addition to endocrine treatment.
First results of the TAILORx trial showed that the Oncotype DX test is able to reliably identify a subgroup of women with early stage, hormone receptor positive breast cancer who can safely avoid chemotherapy.
Some relevant websites for information on cancer clinical trials
Breast Cancer Trials: https://www.breastcancertrials.org.au/home
International Breast Cancer Study Group: http://www.ibcsg.org/Pages/default.aspx
American National Cancer Institute: www.cancer.org
Cancer Research United Kingdom: https://www.cancerresearchuk.org/
The National Health and Medical Research Council Clinical Trials centre: https://www.nhmrc.gov.au
Australian New Zealand Clinical Trials Registry: http://www.breastcancertrials.org.au
Cancer Trials New Zealand: www.cancertrialsnz.ac.nz
Cancer Society of New Zealand: https://cancernz.org.nz/
We acknowledge the wider Breast Care Centre, Regional Cancer Centre and other Waikato Hospital Departmental multidisciplinary teams who support our research. We also acknowledge collaborators from the University of Auckland, the University of Waikato, Investigators from other District Health Board’s and colleagues from the Australia New Zealand Breast Cancer Trials Group.
We also acknowledge WBCRT Trustees, sponsors, grant organisations, and individuals who support our breast cancer research programme. There are many generous groups and people who make our research happen!
For further information on our research please contact:
Telephone: 07 8398726 Ext 97916